Major advances in managing community-acquired pneumonia
Waseem Asrar Khan and Mark Woodhead*

Address: Department of Respiratory Medicine, Manchester Royal Infirmary, Manchester

* Corresponding author: Mark Woodhead (mark.woodhead@cmft.nhs.uk)

F1000Prime Reports 2013, 5:43 (doi:10.12703/P5-43)

This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License (http://creativecommons.org/licenses/by-nc/3.0/legalcode), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. You may not use this work for commercial purposes.

The electronic version of this article is the complete one and can be found at: http://f1000.com/prime/reports/m/5/43

Abstract
This article is a non-systematic review of selected recent publications in community-acquired pneumonia, including a comparison of various guidelines. Risk stratification of patients has recently been advanced by the addition of several useful biomarkers. The issue of single versus dual antibiotic treatment remains controversial and awaits a conclusive randomized controlled trial. However, in the meantime, there is a working consensus that more severe patients should receive dual therapy.

Epidemiology / risk factors
A knowledge of the risk factors for community-acquired pneumonia and those at risk of worse outcomes is important in management of the disease. Mental illness and use of benzodiazepines and angiotensin converting enzyme inhibitors have recently been highlighted as possibly having a causal link with pneumonia [1-3].

Aetiology

Aetiology worldwide
Periodic studies of community-acquired pneumonia microbial aetiology are vital to confirm whether causal pathogen frequencies have, or have not, changed to guide empirical antibiotic therapy strategies. A prospective population-based study in Spain of both inpatients and outpatients found that *Streptococcus pneumoniae* (55.7%) was the most common agent, followed by *Coxiella burnetii* (18.5%), *Mycoplasma pneumoniae* (15.9%), respiratory viruses (14.4%), Chlamydia species (10.6%) and *Legionella pneumophila* (4.4%) [4]. The microbiology of community-acquired pneumonia appears to be unchanged from that found in earlier studies. Patients infected with conventional bacteria such as *S. pneumoniae* had a higher hospitalization rate, higher CURB65 (disease severity) scores at admission and more adverse clinical outcomes, such as severe sepsis, septic shock, ICU admission and longer length of stay compared to those with atypical and viral causes of pneumonia. Limitations in the study included an absence of sputum cultures and possible population bias.

Outpatient community-acquired pneumonia
A total of 568 outpatient community-acquired pneumonia episodes in Barcelona were recently studied [5]. Aetiology was established in a third of these cases and *S. pneumoniae* was again the most common proven pathogen, followed by mycoplasma and then legionella.

Viral causes
In another study, the data for 198 patients were analysed from a prospective cohort of community-acquired pneumonia or healthcare-associated pneumonia in a 28-bed medical intensive care unit (ICU) [6]. These were patients that were severe enough to be admitted to the intensive care unit. The breakdown was that 35% of patients had a bacterial infection and 36% had a viral infection. Of the latter, the following viruses were identified – rhino virus (23.6%), para influenza virus (20.8%), human metapneumovirus (18.1%), influenza virus (16.7%), and respiratory syncytial virus (13.9%). Mortalities of patients with bacterial, viral, and bacterial-viral co-infections were similar. Limitations of the study included a reliance on upper respiratory specimens. Lack of pharmacological therapies for most viral causes limits the value of this information at the current time.
**Novel coronavirus**

A recent case report in Saudi Arabia has led to the discovery of a sixth new coronavirus. The patient had pneumonia and acute respiratory distress syndrome with multi-organ dysfunction syndrome and died 11 days after admission [7]. This has also been recently referred to as the Middle East respiratory syndrome coronavirus.

Human Coronavirus-Erasmus Medical Center (HCoV-EMC) is the first human coronavirus in lineage C of the betacoronavirus genus. Its closest relatives are coronaviruses HKU4 and HKU5 found in bats. Additional cases in the Middle East have raised concerns over the potential for more widespread dissemination.

**Influenza viruses**

Bacterial co-infection was present in 33% of 128 consecutive adult patients hospitalized with a diagnosis of influenza A (H1N1) and community-acquired pneumonia. Predictors of bacterial co-infection included underlying chronic obstructive pulmonary disease (COPD) and a higher platelet count at admission. Bacterial co-infection was not related to increased mortality [8].

H5N1 continues to cause sporadic human infections in Egypt and South East Asia, but more alarming is the recent emergence of H7N9 as a cause of human illness [9]. Cases reported so far suggest a link with birds as the source with little or no human-to-human spread. Severe multi-organ failure with mortality of about one third is reported [10].

**Severity scores**

All guidelines recommend severity scoring tools in conjunction with clinical assessment in adult community-acquired pneumonia management, although controversy remains about which scoring system to use and when to use it.

**PSI score**

Recent systematic reviews showed that all of the standard scoring methods of the pneumonia severity index (PSI), CURB65, and CRB65 showed moderate to good accuracy in predicting 30-day mortality in these patients and risk of death [11] (see Tables 1 and 2 for more details). PSI appeared to have a significant advantage in terms of its negative likelihood ratio, therefore indicating its superior ability at identifying low risk patients.

**CURB65**

A higher positive predictive value than the PSI system suggests that CURB65/CRB65 may be superior for identifying high-risk patients in terms of mortality and decisions with regards to admission of high-risk patients (see Table 3 for more details).

---

**Table 1. PSI scoring**

| Criteria | Points | Add/subtract points |
|----------|--------|---------------------|
| General  |        |                     |
| a) Age in years 1 point per year Add | 1 |       |
| b) Gender 10 points for women Subtract | 10 |       |
| c) Nursing home resident 10 points Add | 10 |       |
| Past medical history |        |                     |
| a) Cancer 30 points Add | 30 |       |
| b) Liver disease 20 points Add | 20 |       |
| c) CHF 10 points Add | 10 |       |
| d) CVA 10 points Add | 10 |       |
| e) CKD 10 points Add | 10 |       |
| Examination findings |        |                     |
| a) Altered consciousness 20 points Add | 20 |       |
| b) Breathing rate >30 rpm 20 points Add | 20 |       |
| c) Systolic BP <90 mmHg 20 points Add | 20 |       |
| d) Temperature not 95-104 F(35-40 C) 15 points Add | 15 |       |
| e) Heart rate > 125 bpm 10 points Add | 10 |       |
| Labs: arterial blood gas (ABG) |        |                     |
| a) Arterial pH <7.35 30 points Add | 30 |       |
| b) PaO2 <60 mmHg (<90% O2 SATS) 10 points Add | 10 |       |
| Labs: Serum Chemistry |        |                     |
| a) Serum sodium <130 mEq/L 20 points Add | 20 |       |
| b) Blood urea nitrogen (BUN) >64 mg/dl 20 points Add | 20 |       |
| c) Serum glucose >250 mg/dl 10 points Add | 10 |       |
| Labs: blood count |        |                     |
| a) Haematocrit <30% 10 points Add | 10 |       |
| Other |        |                     |
| a) Chest Xray- pleural effusion 10 points Add | 10 |       |

Abbreviations: CHF, congestive heart failure; CVA, cerebrovascular accident; CKD, chronic kidney disease

**Table 2. Scoring and interpretation of PSI scoring**

| Scoring | Interpretation |
|---------|----------------|
| Class 1: Points 0: Mortality 0.1% (low risk) | Outpatient management |
| Class 2: Points <70: Mortality 0.6% (low risk) | Outpatient management |
| Class 3: Points 71-90: Mortality 2.8% (low risk) | Consider short observation hospital stay |
| Class 4: Points 91-130: Mortality 8.2% (moderate risk) | Inpatient management |
| Class 5: Points >130: Mortality 29.2% (high risk) | Inpatient management |

**Table 3. Explanation of CURB scoring**

| CURB scoring | Points added |
|--------------|--------------|
| Confusion of new onset (defined as an abbreviated mental test score of 8 or less) | 1 point |
| Urea greater than 7 mmol/l | 1 point |
| Respiratory rate of 30 breaths per minute or greater | 1 point |
| Blood pressure less than 90 mmHg systolic or diastolic blood pressure 60 mmHg or less | 1 point |
| Age 65 or older | 1 point |

The risk of death at 30 days increases as the score increases: 0 points—0.7%, 1 point—3.2%, 2 points—13.0%, 3 points—17.0%, 4 points—41.5%, 5 points—57.0%
CURB65-guided antibiotic therapy was associated with a significant decrease in broad-spectrum antibiotic use. The intervention was safe with no impact on mortality, treatment failure or clinical response [12].

**CRB-65**

A recent study of the CRB65 score investigated whether it was useful in patients with lower respiratory tract infection in a primary care setting but showed that it had little correlation with severe symptom duration or hospitalisation [13]. In this study, however, respiratory rate and blood pressure were infrequently measured (22.7% and 31.9% respectively), suggesting that clinical practice would have to change if this score were to be used routinely.

Another study of CRB65 score investigated whether the cut off age of 65 had any impact in terms of severity of patients presenting with pneumonia [14]. This study included nearly 700,000 patients hospitalised in Germany between 2008 and 2010. The age of 65 (resulting in CRB≥65) was a reasonable threshold for the assessment of the risk of death from community-acquired pneumonia in the total population, although age group 80 (CRB≥80) had the highest risk of death [14]. In patients aged less than 65 years, death prediction was best below age of 50, with excellent prediction of low-risk patients. In patients aged 65 or over with nursing home-acquired pneumonia, the optimal age group for death prediction continued to be 80 (CRB≥80).

**ATS / IDSA severity criteria**

The American Thoracic Society-Infectious Diseases Society of America (ATS-IDSA) rule consists of two major (mechanical ventilation or shock) and nine minor criteria. The rule is considered positive in the presence of one major or three minor criteria. A meta-analysis found the ATS minor criteria, S-community-acquired pneumonia score, and SMART-COP to have good predictive characteristics for ICU admission [15].

**Biomarkers**

**Serum glucose**

A recent predictive cohort study [16] found that an increased serum glucose level at admission to hospital and no pre-existing diabetes was a predictor of death at 28 and 90 days in 6891 patients with community-acquired pneumonia. Whether this adds to the use of a scoring system and whether blood glucose management alters the outcome in community-acquired pneumonia is not known. Although the PSI scoring system includes serum glucose, this paper investigated serum glucose as an independent risk factor in predicting death in patients with community-acquired pneumonia.

**Procalcitonin**

A systematic review of procalcitonin as a prognostic marker in community-acquired pneumonia found that complications during admission, severity of disease and death within a month correlated with high levels of procalcitonin but no definite cut off level was found. Procalcitonin with a cut-off point of 0.15 ng/ml was the best predictor for bacterial aetiology and to select patients eligible for outpatient care in another study [17]. They suggested that levels of procalcitonin and C reactive protein positively correlate with increasing severity of community-acquired pneumonia and may have a role in disease prediction, perhaps in patients with low CURB65 scores [18]. Limitations of the study included study heterogeneity and risk of publication bias. Using a procalcitonin algorithm on antibiotic guidance reduced antibiotic use without increased complications. Good compliance with the procalcitonin algorithm was possible in real-life conditions but had to be reinforced by other measures to achieve an optimal benefit [19]. Limitations here included observational design and unclear diagnostic criteria.

**Pro-adrenomedullin**

Another recent study showed that increased pro-adrenomedullin (proADM) levels closely correlated with increased severity scores and showed a predictive power in both long and short term complications in patients with community-acquired pneumonia, especially when used in conjunction with PSI and CURB65. An admission proADM level of 0.646 nmol correlated in such a fashion that 92% of the 139 patients in PSI classes 4 and 5 would have been correctly classified [20]. This was a single hospital study and serial biomarkers were not used throughout the study. Another study also reflected that proADM may be helpful in individual risk stratification of community-acquired pneumonia patients with a high PSI score in the Emergency Department, allowing better identification of patients at risk of death [21].

**IL-6, IL-10 and lipopolysaccharide-binding protein**

The highest levels of IL-6, IL-10 and lipopolysaccharide-binding protein (LBP) correlated best with a CURB65 score of 3 and 4 and the accuracy of CURB65 was greatly enhanced by the use of IL-6 levels [22]. These are best used as a predictor of severity of community-acquired pneumonia rather than prognosis.

**Serum cortisol**

Serum cortisol level predicts mortality and critical disease independently of clinical scores and inflammatory biomarkers. A recent study showed that increased serum cortisol level was associated with the development of critical disease and increased 30-day-mortality in...
hospitalised community-acquired pneumonia-patients. Serum cortisol level improved the predictive power of the CRB65 score and showed independent prognostic significance [23]. The main limitation of the study was that controlling for the time point of blood sampling could not be done, so diurnal concentration changes may have influenced the results.

Management
Guidelines
See Table 4 for a comparison of selected features in National and International community-acquired pneumonia Guidelines, drawn from [24-26].

Risk stratification and admission to ICU
ATS/IDSA
These guidelines make it quite clear that severity illness scores such as CURB65 and PSI should be used to identify patients for outpatient management. Physicians are advised to take into account factors such as availability of outpatient support resources. CURB65 scores ≥2 suggest hospital admission. Direct admission to ICU should be made upon factors such as septic shock requiring vasopressor support and/or respiratory failure requiring intubation and ventilation.

British thoracic society
The British Thoracic Society (BTS) guidelines are quite clear that the scoring system of CURB65 in conjunction with clinical assessment is the main requirement in deciding point of care admission of community-acquired pneumonia patients. Those with a score of CURB65 0 or 1 can be managed quite safely as outpatients. Patients with CURB65 score of 2 should be considered for hospital admission, as there is a significant increase in mortality with this group. Those with CURB65 scores of 3 and above should be reviewed by senior clinicians, and patients with CURB65 scores of 4 and above should be seriously considered for ICU admission. Persistent hypoxia, progressive hypercapnoea, shock or reduced consciousness are indications for transfer to critical care.

European respiratory society / european society of clinical microbiology and infectious diseases
These guidelines make it very clear that the decision to hospitalise community-acquired pneumonia patients is a clinical decision. A CRB score of 1 or more (except if age ≥65 is the only criterion met) suggests that hospitalisation should be considered. Factors such as acute respiratory failure, septic shock and decompensated comorbidities should be considered for early referral to intensive care.

Antibiotics – dual vs single
There has always been a debate with regards to the value of single (β-lactam or macrolide) versus dual (β-lactam plus macrolide) antibiotic therapy – a question that has never been addressed by a good-quality randomised controlled trial.

Although there are some differences in the antibiotics recommended for first-line treatment in the Guidelines (Table 4) there is consensus that patients with more severe community-acquired pneumonia should be given dual therapy. A total of 23 studies with approximately 137,000 patients were included in a recent meta-analysis of the efficacy of macrolides in patients hospitalised with community-acquired pneumonia [27]. Macrolide-based regimens were associated with a significant 22% reduction in mortality compared to non-macrolides.

Table 4. Recommended community-acquired pneumonia therapy and management from published international guidelines

|                  | BTS guidelines [24] | ATS/IDSA guidelines [25] | ERS/ESCMID guidelines [26] |
|------------------|---------------------|--------------------------|----------------------------|
| **Low severity patients** |                     |                          |                            |
|                   | Use CURB65 score with clinical judgement Treat with oral amoxicillin or (doxycycline or clarithromycin if hypersensitive). | Use CURB65 or PSI score to guide Outpatient treatment Stratify by risk for drug resistant S. pneumoniae Low risk: Treat with macrolide or doxycycline High risk: Treat with respiratory fluoroquinolone or β-lactam+macrolide | Use CRB65 to guide Outpatient treatment Treat with one of: aminopenicillin ± macrolide Aminopenicillin/β-lactamase inhibitor ± macrolide Non-antipseudomonal cefalosporin Cefotaxime or ceftriaxone ± macrolide Levofloxacin Moxifloxacin Penicillin ± macrolide Consider ICU for sepsis or >2 minor severity criteria Increased Comorbidities or prior antimicrobials (within 3 months) treat with respiratory fluoroquinolone or beta lactam + macrolide iv Consider ICU for respiratory failure or sepsis or >2 minor severity criteria Stratify by risk for Pseudomonas aeruginosa Non-antipseudomonal treatment with cefalosporin III + macrolide Or Moxifloxacin or levofloxacin ± non-antipseudomonal cefalosporin III |
| **Moderate/high severity patients** | CURB65 score 3 or more consider ICU Treat with β-lactam plus macrolide iv | Consider ICU for sepsis or >2 minor severity criteria Increased Comorbidities or prior antimicrobials (within 3 months) treat with respiratory fluoroquinolone or beta lactam plus macrolide iv | |

*These are not necessarily the terms used in the guidelines but give a broad translation of what the guidelines state.*
However, this benefit did not extend to randomised controlled trials or patients that received guideline-concordant antibiotics (also found in a study of community-acquired pneumonia patients with severe sepsis [26]). Guideline-concordance may be more important than choice of antibiotic when treating community-acquired pneumonia [28].

Both studies point towards the need for good adherence to hospital prescribing guidelines. A very careful study conducted in 2007 came to a verdict that the benefit of dual therapy versus single therapy cannot be reliably assessed in observational studies, since the propensity to prescribe these regimens differs markedly [29]. Taking this into account may skew the results of previous studies comparing single and dual therapy.

A total of 5240 patients were included in an audit of adult community-acquired pneumonia management in the UK [30]. The death rate was high at 24%. Patients treated with dual therapy had a significantly lower death rate in both moderate- and high-severity groups compared with β-lactam therapy alone.

As in other studies, the propensity to prescribe could not be corrected for. The concordance of findings with other cohort studies may suggest a real result, but randomized controlled trial results are required to confirm this.

Corticosteroids
These have often been an intervention of last resort in the failing patient. Studies in meningitis and pneumocystis pneumonia support their role in infection control but, until recently, studies in community-acquired pneumonia were absent. The conflicting results from studies in sepsis confirmed the need for community-acquired pneumonia-specific studies, preferably randomised controlled trials. A recent double blind, placebo-controlled randomized controlled trial using 40 mg prednisolone for 7 days as the intervention found that there were no beneficial effects of adjunctive corticosteroids in patients hospitalized with community-acquired pneumonia. Other outcomes of the study showed that clinical cure was equal in both groups at Day 7 [31]. A similar study using dexamethasone for 3 days did find a reduced hospital stay of one day in the steroid-treated patients, but a large number of exclusions and lack of control for other factors limiting length of stay limited the usefulness of this study [32]. The only other randomised controlled trial evaluating patients with community-acquired pneumonia admitted to ICU found a reduction in mortality using hydrocortisone [33]. The small patient number and absence of any deaths in the intervention arm mean that these findings cannot be generalised unless reproduced in other studies. A role for steroids in patients with community-acquired pneumonia is yet to be proved.

Process of care – choice of quality indicators
Pay for performance programs are being adopted internationally to try and improve patient outcomes with limited evidence of their effectiveness. One reason for this may be lack of robust evidence to support the quality indicators used [34]. Conversely, in a US study of 2076 patients, there was no association with either individual or combinations of quality indicator compliance and mortality [35]. In a study of 30-day inpatient mortality amongst 143,435 adults admitted with pneumonia, heart failure, or acute myocardial infarction to 24 UK hospitals covered by a pay-for-performance program [36], an association between use of the program and significant mortality reduction was found when compared to other UK hospitals not using the pay-for-performance program. Of the three included conditions, however, only pneumonia was found to have an association with mortality reduction in the pay-for-performance group [36].

Not only are the quality measures controversial but so are the methods of implementation. A randomized controlled trial investigated the implementation of a three-step strategy of early mobilisation, objective criteria for switching to oral therapy and for deciding on hospital discharge, and showed interesting results [37]. The use of a three-step critical pathway was safe and effective in reducing the duration of intravenous antibiotic therapy and length of hospital stay for community-acquired pneumonia patients and this did not adversely affect patient outcomes [37]. The jury is still out with regards to performance-related programmes but there is a need to develop further randomised controlled trials.

Summary and future directions
The last few years have seen some major advances in the management of community-acquired pneumonia. Risk stratification of patients has recently been advanced by the addition of several useful biomarkers. The issue of single versus dual antibiotic treatment remains controversial and awaits a conclusive randomized controlled trial. However, in the meantime, there is a working consensus that more severe patients should receive dual therapy.

Abbreviations
ATS-IDSA, American Thoracic Society-Infectious Diseases Society of America; BTS, British Thoracic Society; COPD, chronic obstructive pulmonary disease; HCoV-EMC, Human Coronavirus-Erasmus Medical Center; ICU, intensive care unit; LBP, lipopolysaccharide-binding protein; proADM, pro-adrenomedullin; PSI, pneumonia severity index.
Disclosure
“The authors declare that they have no disclosures.”

References
1. Seminog OO, Goldacre MJ: Risk of pneumonia and pneumococcal disease in people with severe mental illness: English record linkage studies. Thorax 2013, 68:171-6.

2. Obiora E, Hubbard R, Sanders RD, Myles PR: The impact of benzodiazepines on occurrence of pneumonia and mortality from pneumonia: a nested case-control and survival analysis in a population-based cohort. Thorax 2013, 68:163-70.

3. Caldeira D, Alarcão J, Vaz-Carneiro A, Costa J: Risk of pneumonia associated with use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers: systematic review and meta-analysis. BMJ 2012, 345:e4260.

4. Capelastegui, et al.: Etiology of community-acquired pneumonia in a population-based study: Link between etiology and patients characteristics, process-of-care, clinical evolution and outcomes BMC Infectious Diseases 2012, 12:134.

5. Cillóniz C, Ewig S, Polverino E, Marcos MA, Prina E, Sellares J, Ferrer M, Ortega M, Gabarrús A, Mensa J, Torres A: Community-acquired pneumonia in outpatients: aetiology and outcomes. Eur Respir J 2012, 40:931-8.

6. Choi S, Hong S, Ko G, Lee Y, Park Hj, Park S, Moon SM, Cho O, Park K, Chong YP, Kim S, Huh JW, Sung H, Do K, Lee S, Kim M, Jeong J, Lim C, Kim YS, Woo JH, Koh Y: Viral infection in patients with severe pneumonia requiring intensive care unit admission. Am J Respir Crit Care Med 2012, 186:325-32.

7. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus ADME, Fouchier RAM: Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012, 367:1814-20.

8. Cillóniz C, Ewig S, Menéndez R, Ferrer M, Polverino E, Reyes S, Gabarrús A, Marcos MA, Cordoba J, Mensa J, Torres A: Bacterial co-infection with H1N1 infection in patients admitted with community acquired pneumonia. J Infect 2012, 65:223-30.

9. Gao R, Cao B, Hu Y, Feng Z, Wang D, Hu W, Chen J, Jie Z, Qiu H, Xu K, Xu X, Lu H, Zhu W, Gao Z, Xiang N, Shen Y, He Z, Gu Y, Zhang Z, Yang Y, Zhao X, Zhou L, Li X, Zou S, Zhang Y, Li X, Yang L, Guo J, Dong J, Li Q; et al.: Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med 2013, 368:1888-97.

10. Parry J: H7N9 avian flu kills seven and infects 23 in China. BMJ 2013, 346:f2222.

11. Chalmers JD, et al.: Severity assessment tools to guide ICU admission in community-acquired pneumonia: systematic review and meta-analysis. Intensive Care Med (2011) 37:1409–1420 Thorax 2013, 68:39-47.

12. Chalmers JD, Singanayagam A, Akram AR, Choudhury G, Mandal P, Hill AT: Safety and efficacy of CURB65-guided antibiotic therapy in community-acquired pneumonia. J Antimicrob Chemother 2011, 66:416-23.

13. Francis NA, et al.: Severity assessment for lower respiratory tract infections: Potential use and validity of CRB-65 in primary care Primary Care Respiratory Journal 2012 Mar;21(1): 65-70.

14. Ewig S, Bauer T, Richter K, Szczesnycy J, Heller G, Strauss R, Welte T: Prediction of in-hospital death from community-acquired pneumonia by varying CRB-age groups. Eur Respir J 2013, 41:917-22.

15. Marti C, Garin N, Grosgeurin O, Poncet A, Combesgue C, Carballo S, Pierrier A: Prediction of severe community-acquired pneumonia: a systematic review and meta-analysis. Crit Care 2012, 16:R141.

16. Lepper PM, Otz S, Nuesch E, Eynatten M von, Schumann C, Pletz MW, Mealing NM, Welte T, Bauer TT, Suttorp N, Juni P, Bals R, Rohde G: Serum glucose levels for predicting death in patients admitted to hospital for community acquired pneumonia: prospective cohort study. BMJ 2012, 344:e3397.

17. Berg P, Lindhardt BØ: The role of procalcitonin in adult patients with community-acquired pneumonia–a systematic review. Dan Med J 2012, 59:A337.

18. España PP, Capelastegui A, Billao A, Diez R, Izquierdo F, Lopez de Goicoeetxea MJ, Gamazo J, Medel F, Salgado J, Gorostiza I, Quintana JM: Utility of two biomarkers for directing care among patients with non-severe community-acquired pneumonia. Eur J Clin Microbial Infect Dis 2012, 31:3397-405.

19. Albrich WC, Dusemund F, Bucher B, Meyer S, Thomann R, Kuhn F, Bassetti S, Sprenger M, Bachli E, Sigrac T, Schwietert M, Amin D, Hausfater P, Carre E, Galliat J, Schuectz P, Regez K, Bossart R, Schild U, Mueller B: Effectiveness and safety of procalcitonin-guided antibiotic therapy in lower respiratory tract infections in “real life”: an international, multicenter poststudy survey (ProREAL). Arch Intern Med 2012, 172:715-22.

20. Bello S, Lasierra AB, Mincholé E, Fandos S, Ruiz MA, Vera E, Pablo F de, Ferrer M, Menendez R, Torres A: Prognostic power of proadrenomedullin in community-acquired pneumonia is independent of aetiology. Eur Respir J 2012, 39:1144-55.

21. Courtais C, Kuster N, Dupuy A, Folschviller M, Jreige R, Bargnoux A, Guiot J, Lefebvre S, Cristol J, Sebbane M: Proadrenomedullin, a useful tool for risk stratification in high Pneumonia Severity Index score community acquired pneumonia. Am J Emerg Med 2013, 31:215-21.

22. Zobel K, Martus P, Pletz MW, Ewig S, Prediger M, Welte T, Bühling F: Interleukin 6, lipopolysaccharide-binding protein and interleukin 10 in the prediction of risk and etiologic patterns in patients with community-acquired pneumonia: results from hubs.
the German competence network community-acquired pneumoniaNETZ. BMC Pulm Med 2012; 12:6.

23. Kolditz M, Hoffken G, Martus P, Rohde G, Schütte H, Bals R, Sutoor N, Pletz MW: Serum cortisol predicts death and critical disease independently of CRB-65 score in community-acquired pneumonia: a prospective observational cohort study. BMC Infect Dis 2012; 12:90.

24. Lim WS, Baudouin SV, George RC, Hill AT, Jamieson C, Le Jeune I, Macfarlane JT, Read RC, Roberts HJ, Levy ML, Wani M, Woodhead MA: BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 2009; 64(Suppl 3):iii1-55.

25. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM, Musher DM, Niederman MS, Torres A, Whitney CG: Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44(Suppl 2):S27-72.

26. Woodhead M, Blasi F, Ewig S, Garau J, Huchon G, Leven M, Ortwist A, Schaberg T, Torres A, van der Heijden G, Verheij TJM: Guidelines for the management of adult lower respiratory tract infections—full version. Clin Microbiol Infect 2011; 17(Suppl 6):E1-39.

27. Asadi L, Sligl WI, Eurich DT, Colmers IN, Tjosvold L, Marrie TJ, Maunder SR: Macrolide-based regimens and mortality in hospitalized patients with community-acquired pneumonia: a systematic review and meta-analysis. Clin Infect Dis 2012; 55:371-80.

28. Menéndez R, Torres A, Reyes S, Zalacain R, Capelastegui A, Aspa J, Borderías L, Martín-Villasclaras JJ, Bello S, Alfageme I, Castro FR de, Rello J, Molinos L, Ruiz-Manzano J: Initial management of pneumonia and sepsis: factors associated with improved outcome. Eur Respir J 2012; 39:156-62.

29. Paul M, et al: The need for macrolides in hospitalised community-acquired pneumonia: propensity analysis Eur Respir J 2007; 30:525-531.

30. Rodrigo C, McKeever TM, Woodhead M, Lim WS: Single versus combination antibiotic therapy in adults hospitalised with community acquired pneumonia. Thorax 2013; 68:493-5.

31. Snijders D, Daniels JMA, Graaff CS de, van der Werf TS, Boersma WG: Efficacy of corticosteroids in community-acquired pneumonia: a randomized double-blinded clinical trial. Am J Respir Crit Care Med 2010; 181:975-82.

32. Meijvis SCA, Hardeman H, Remmelts HHF, Heijligenberg R, Rijkers GT, van Velzen-Blad H, Voorn GP, van de Garde EMW, Endeman H, Grutters JC, Bos WJW, Biesma DH: Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial. Lancet 2011; 377:2023-30.

33. Confalonieri M, Urbino R, Potena A, Piattella M, Parigi P, Puccio G, Della Porta R, Giorgio C, Blasi F, Ungerber R, Meduri GU: Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med 2005; 171:142-8.

34. Wilson KC, Schünemann HJ: An appraisal of the evidence underlying performance measures for community-acquired pneumonia. Am J Respir Crit Care Med 2011; 183:1454-62.

35. Lee JS: Processes of Care and Outcomes for Community-Acquired Pneumonia The American Journal of Medicine (2011) 124:1175.

36. Sutton M, Nikolova S, Boaden R, Lester H, McDonald R, Roland M: Reduced mortality with hospital pay for performance in England. N Engl J Med 2012; 367:1821-8.

37. Carratalà J, García-Vidal C, Ortega L, Fernández-Sabé N, Clemente M, Albero G, López M, Castellsague X, Dorca J, Verdaguer R, Martínez-Montañé J, Manresa F, Gudiol F: Effect of a 3-step critical pathway to reduce duration of intravenous antibiotic therapy and length of stay in community-acquired.